Mechanism of Action
Tarlatamab-dlle is a bispecific T-cell engager that binds to DLL3 expressed on the surface of cells, including tumor cells, and CD3 expressed on the surface of T cells. Tarlatamab-dlle causes T-cell activation, release of inflammatory cytokines, and lysis of DLL3-expressing cells. Tarlatamab-dlle…
Indications (2)
Clinical Trials (5)
A Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2
Tarlatamab for the Treatment of Extensive Stage Small-cell Lung Cancer
Refractory Advanced diGestive Neuroendocrine Carcinomas Treated With tARlatamab
Combination of Tarlatamab and Temozolomide in Patients With Central Nervous System Tumors
A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)